Comparative Pharmacology
Head-to-head clinical analysis: EXTINA versus GRISACTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXTINA versus GRISACTIN.
EXTINA vs GRISACTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antifungal agent that inhibits the enzyme 14α-demethylase, blocking the conversion of lanosterol to ergosterol, an essential component of fungal cell membranes.
Binds to microtubules and disrupts mitotic spindle formation, inhibiting fungal cell division.
2.5% to 3.5% solution applied topically twice daily for 4 weeks.
500 mg orally once daily or 250 mg orally twice daily for dermatophyte infections.
None Documented
None Documented
Terminal elimination half-life is approximately 24-32 hours in adults, allowing once-daily dosing. Half-life may be prolonged in patients with renal impairment.
Terminal elimination half-life: 9–24 hours (mean ~14 hours). Clinical context: Steady-state achieved in 3–5 days; once-daily dosing is effective due to prolonged half-life.
Primarily renal excretion of unchanged drug (approximately 80-90% of the absorbed dose), with minor hepatic metabolism and fecal elimination (<10%).
Renal: <1% as intact drug; fecal: >99% as metabolites (mainly 6-demethylgriseofulvin glucuronide) via bile; negligible biliary excretion of parent compound.
Category C
Category C
Antifungal
Antifungal